Meryl is a consultant to the biopharma industry in the areas of quality assurance, quality and vendor management, outsourcing, and business process optimization. Previously, she was the VP of QA and Business Excellence for SynteractHCR, a mid-sized global CRO, where she participated in company integration activities, global harmonization, and enhancement of quality processes. Meryl has also served as the Director of Strategic Outsourcing for Teva Pharmaceuticals, Bristol Myers Squibb and Amgen; for Teva and BMS, she originated these departments. Meryl has worked for several central laboratories, including LabCorp, MDS Pharma, Quest Diagnostics and ACM, in functions including Project Management, Operations, Quality, client relationship management, global harmonization, and Biorepository management. During her 19 year tenure at Bristol Myers Squibb, she was instrumental in the conceptualization, implementation, growth, and marketing of the BMS Clinical Laboratory, in support of the phase I unit as well as Phase II-IV trials.
Meryl holds a BS in Medical Technology from Rutgers University and an MBA from Fairleigh Dickinson University.